ICAD(Delisted)
iCAD·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 1
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ICAD
Icad, Inc.
A global medical technology leader providing innovative cancer detection and therapy solutions
1 Avenue du Général de Gaulle, FR-92800 Puteaux-la-Défense, France
--
ICAD, Inc., was founded in 1984 as Howtek Corporation. Since then, the company has established itself as the industry's leading provider of CAD (computer-aided design) solutions for mammography. ICAD offers a comprehensive range of high-performance upgradeable products for mammography, including digital X-ray, computed radiography and film-based mammography. These solutions enable radiologists to better serve patients by identifying pathologies and locating cancer locations. Early detection of cancer is the key to better diagnosis, less aggressive treatment, and lower treatment costs. As an assistant for mammography, CAD soon became the standard for breast cancer treatment and detection, helping radiologists improve clinical outcomes while speeding up workflows.
Company Financials
EPS
ICAD has released its 2025 Q1 earnings. EPS was reported at -0.02, versus the expected -0.06, beating expectations. The chart below visualizes how ICAD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ICAD has released its 2025 Q1 earnings report, with revenue of 4.87M, reflecting a YoY change of -1.61%, and net profit of -833.00K, showing a YoY change of 31.83%. The Sankey diagram below clearly presents ICAD's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
